To develop medical countermeasures (MCMS) that treat antibiotic resistant infections.

Active Definitive Contract Awarded Last action

Contract number
75A50120C00177
Awardee
Awarding agency
Obligated
$79,146,088

Award facts

Contract value 59% obligated
  • $99,146,088.00 Current, with exercised options
  • $134,146,088.00 Potential, with all options
Completion date 54% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
Boston, MA 02116, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00018 $0
Supplemental Agreement for work within scope P00016 $0
Supplemental Agreement for work within scope P00015 $0
Other Administrative Action P00014 $0
Supplemental Agreement for work within scope P00013 $12,500,000
Supplemental Agreement for work within scope P00012 $5,500,000
Supplemental Agreement for work within scope P00011 $10,000,000
Supplemental Agreement for work within scope P00010 $0
Supplemental Agreement for work within scope P00009 $15,000,000
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Supplemental Agreement for work within scope P00006 $5,000,000
Supplemental Agreement for work within scope P00005 $0
Other Administrative Action P00004 $0
Exercise an Option P00003 $23,783,021
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $7,363,067
Show all 18

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Vedanta Biosciences, Inc. for development of medical countermeasures treating antibiotic-resistant infections on September 28, 2020, with a ceiling value of $134.1 million under cost-sharing pricing and no set-aside.

The originating solicitation is a BARDA Broad Agency Announcement seeking advanced research and development of medical countermeasures against biological, chemical, radiological, nuclear, and pandemic threats. This award funds clinical development of VE303, a live biotherapeutic product for prevention of recurrent Clostridium difficile infection, and supports development of VE707, an investigational live biotherapeutic product designed to eliminate intestinal carriage of multidrug-resistant organisms including carbapenem-resistant Enterobacteriaceae, extended-spectrum beta-lactamase producers, and vancomycin-resistant Enterococci. Place of performance is Boston, MA. The contract runs through December 31, 2031.

Quick answers

Who was awarded contract 75A50120C00177?

75A50120C00177 was awarded to Vedanta Biosciences, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 28, 2020.

How much is contract 75A50120C00177 worth?

The government has obligated $79,146,088 on 75A50120C00177. Its current value, with exercised options, is $99,146,088. Its potential value, with all options, is $134,146,088.

Was contract 75A50120C00177 competed?

The extent of competition for 75A50120C00177 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login